• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一名复发型多发性硬化症患者在接受特立氟胺治疗时发生致命性中毒性表皮坏死松解症。

Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis.

作者信息

Gerschenfeld Gaspard, Servy Amandine, Valeyrie-Allanore Laurence, de Prost Nicolas, Cecchini Jérôme

机构信息

Service de Réanimation Médicale, Assistance Publique - Hôpitaux de Paris, Groupe Henri Mondor - Albert Chenevier, Créteil, France.

Service de Dermatologie et Centre de Référence des dermatoses bulleuses immunologiques et toxiques, Assistance Publique - Hôpitaux de Paris, Groupe Henri Mondor - Albert Chenevier, Créteil, France.

出版信息

Mult Scler. 2015 Oct;21(11):1476-7. doi: 10.1177/1352458515596601. Epub 2015 Jul 21.

DOI:10.1177/1352458515596601
PMID:26199352
Abstract

We report a case of toxic epidermal necrolysis in a 46-year-old woman on teriflunomide treatment. Such a severe adverse cutaneous drug reaction with this new therapy for relapsing forms of multiple sclerosis should be early recognized in order to ensure the rapid withdrawal of the drug.

摘要

我们报告了一例46岁接受特立氟胺治疗的女性发生中毒性表皮坏死松解症的病例。对于这种用于复发型多发性硬化症的新疗法所引发的如此严重的药物性皮肤不良反应,应尽早识别,以便确保迅速停药。

相似文献

1
Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis.一名复发型多发性硬化症患者在接受特立氟胺治疗时发生致命性中毒性表皮坏死松解症。
Mult Scler. 2015 Oct;21(11):1476-7. doi: 10.1177/1352458515596601. Epub 2015 Jul 21.
2
A case of lymphoma in a patient on teriflunomide treatment for relapsing multiple sclerosis.一名正在接受特立氟胺治疗复发型多发性硬化症的患者发生淋巴瘤的病例。
Mult Scler Relat Disord. 2017 Oct;17:92-94. doi: 10.1016/j.msard.2017.07.001. Epub 2017 Jul 3.
3
Palmar pustular psoriasis associated with teriflunomide treatment.手掌脓疱性银屑病与特立氟胺治疗相关。
Mult Scler Relat Disord. 2019 Jan;27:400-402. doi: 10.1016/j.msard.2018.11.020. Epub 2018 Nov 19.
4
A case of drug-induced bullous pemphigoid associated with teriflunomide: A patient with relapsing multiple sclerosis.与特立氟胺相关的药物诱导性大疱性类天疱疮病例:一位复发性多发性硬化症患者。
Mult Scler Relat Disord. 2020 Aug;43:102157. doi: 10.1016/j.msard.2020.102157. Epub 2020 May 15.
5
Severe hypertriglyceridemia associated with teriflunomide in a patient with multiple sclerosis: A case report.与多发性硬化症患者的特立氟胺相关的严重高甘油三酯血症:一例报告。
Mult Scler. 2018 Sep;24(10):1383-1385. doi: 10.1177/1352458518761185. Epub 2018 Feb 23.
6
Rebound syndrome after teriflunomide cessation in a patient with multiple sclerosis.多发性硬化症患者停用特立氟胺后出现反弹综合征。
J Neurol Sci. 2017 Sep 15;380:79-81. doi: 10.1016/j.jns.2017.07.014. Epub 2017 Jul 9.
7
▼Teriflunomide for multiple sclerosis.▼用于治疗多发性硬化症的特立氟胺。
Drug Ther Bull. 2014 Jul;52(7):81-4. doi: 10.1136/dtb.2014.7.0267.
8
"Nail loss after teriflunomide treatment: A new potential adverse event".“替西罗莫司治疗后出现指甲缺失:一种新的潜在不良反应”。
Mult Scler Relat Disord. 2017 Nov;18:170-172. doi: 10.1016/j.msard.2017.09.029. Epub 2017 Sep 25.
9
Safety of teriflunomide for the management of relapsing-remitting multiple sclerosis.特立氟胺治疗复发缓解型多发性硬化症的安全性。
Expert Opin Drug Saf. 2015 May;14(5):749-59. doi: 10.1517/14740338.2015.1014795. Epub 2015 Feb 17.
10
Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions.来自四项安慰剂对照的特立氟胺研究及扩展研究的汇总安全性和耐受性数据。
Mult Scler Relat Disord. 2016 Jan;5:97-104. doi: 10.1016/j.msard.2015.11.006. Epub 2015 Nov 10.

引用本文的文献

1
Teriflunomide-Induced Palmoplantar Pustular Psoriasis: Case Report and Review of the Literature.来氟米特诱发掌跖脓疱型银屑病:病例报告及文献复习
Cureus. 2023 Aug 2;15(8):e42845. doi: 10.7759/cureus.42845. eCollection 2023 Aug.
2
Lichenoid Drug Eruption Induced by Teriflunomide.来氟米特诱发的苔藓样药疹
Ann Indian Acad Neurol. 2023 May-Jun;26(3):275-277. doi: 10.4103/aian.aian_27_23. Epub 2023 Jun 15.
3
Current Pharmacogenetic Perspective on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症的当前药物遗传学观点
Front Pharmacol. 2021 Apr 26;12:588063. doi: 10.3389/fphar.2021.588063. eCollection 2021.
4
Safety of Newer Disease Modifying Therapies in Multiple Sclerosis.新型多发性硬化症疾病修正疗法的安全性
Vaccines (Basel). 2020 Dec 26;9(1):12. doi: 10.3390/vaccines9010012.
5
Risks and risk management in modern multiple sclerosis immunotherapeutic treatment.现代多发性硬化症免疫治疗中的风险与风险管理
Ther Adv Neurol Disord. 2019 Apr 1;12:1756286419836571. doi: 10.1177/1756286419836571. eCollection 2019.
6
The sequence of disease-modifying therapies in relapsing multiple sclerosis: safety and immunologic considerations.复发型多发性硬化症中疾病修正疗法的顺序:安全性和免疫学考虑。
J Neurol. 2017 Dec;264(12):2351-2374. doi: 10.1007/s00415-017-8594-9. Epub 2017 Sep 6.
7
Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.多发性硬化症治疗中的跨学科风险管理
Dtsch Arztebl Int. 2016 Dec 26;113(51-52):879-886. doi: 10.3238/arztebl.2016.0879.
8
From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis.从来氟米特到特立氟胺:多发性硬化治疗中的药物研发及免疫抑制口服药物
Curr Neuropharmacol. 2017;15(6):874-891. doi: 10.2174/1570159X14666161208151525.
9
Cutaneous Adverse Effects of Neurologic Medications.神经科药物的皮肤不良反应
CNS Drugs. 2016 Mar;30(3):245-67. doi: 10.1007/s40263-016-0318-7.
10
Multiple sclerosis--new treatment modalities.多发性硬化症——新的治疗方式
Indian J Med Res. 2015 Dec;142(6):647-54. doi: 10.4103/0971-5916.174543.